Uniqure NV (NASDAQ:QURE) was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 1,071 call options on the stock. This represents an increase of 1,499% compared to the average volume of 67 call options.
Shares of QURE traded down $1.40 on Friday, reaching $29.89. 321,512 shares of the stock traded hands, compared to its average volume of 348,097. The stock has a market cap of $1.36 billion, a PE ratio of -10.17 and a beta of 0.27. The company has a current ratio of 8.36, a quick ratio of 8.36 and a debt-to-equity ratio of 0.06. Uniqure has a 12 month low of $9.47 and a 12 month high of $43.23.
Uniqure (NASDAQ:QURE) last announced its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.04. Uniqure had a negative return on equity of 72.12% and a negative net margin of 677.98%. The firm had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $3.37 million. Equities analysts forecast that Uniqure will post -2.44 earnings per share for the current fiscal year.
Several equities research analysts have commented on the stock. Cantor Fitzgerald set a $58.00 price target on shares of Uniqure and gave the stock a “buy” rating in a research report on Wednesday. BidaskClub cut Uniqure from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 28th. HC Wainwright lifted their target price on Uniqure from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, September 24th. Cowen reaffirmed a “buy” rating on shares of Uniqure in a research note on Monday, August 13th. Finally, Janney Montgomery Scott reiterated a “buy” rating on shares of Uniqure in a report on Wednesday, August 8th. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $45.56.
Large investors have recently made changes to their positions in the business. Quantbot Technologies LP grew its holdings in shares of Uniqure by 3,972.6% during the first quarter. Quantbot Technologies LP now owns 5,498 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 5,363 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its holdings in shares of Uniqure by 276.5% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,400 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 4,700 shares during the last quarter. Financial Gravity Wealth Inc. bought a new stake in shares of Uniqure during the first quarter worth $177,000. Gagnon Securities LLC bought a new stake in shares of Uniqure during the second quarter worth $209,000. Finally, Jane Street Group LLC bought a new stake in shares of Uniqure during the first quarter worth $224,000. Hedge funds and other institutional investors own 59.32% of the company’s stock.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Further Reading: Marijuana Stocks Investing Considerations
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.